Overview about Candida auris: What's up 12 years after its first description?

Autor: Guillaume Desoubeaux, Alix T. Coste, Christine Imbert, Christophe Hennequin
Přispěvatelé: Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lausanne = University of Lausanne (UNIL), Ecologie et biologie des interactions (EBI), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Gestionnaire, HAL Sorbonne Université 5
Rok vydání: 2021
Předmět:
Zdroj: Journal of Medical Mycology = Journal de Mycologie Médicale
Journal of Medical Mycology = Journal de Mycologie Médicale, 2022, 32 (2), pp.101248. ⟨10.1016/j.mycmed.2022.101248⟩
ISSN: 1773-0449
1156-5233
DOI: 10.1016/j.mycmed.2022.101248⟩
Popis: International audience; Candida auris has been described as an emerging yeast species during the last decade. As many as 25% of its strains may naturally exhibit multi-drug resistance to the currently available antifungal drugs. Probably due to its ability to survive more than two weeks on inert surfaces, several large outbreaks have been reported, primarily due to nosocomial transmissions. In addition, due to a rapid worldwide spreading, C. auris is now considered as a major public health threat. This review aims at describing the current knowledge about C. auris, with specific focuses on its global epidemiology, virulence features, most reliable diagnostic approaches, and the current and future therapeutic options.
Databáze: OpenAIRE
Externí odkaz: